T2 Biosystems, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-11-24: Form 8-K/A; Period of report 2023-10-31; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2023-11-01: Form 8-K; Period of report 2023-10-31; Description 8.01 Other Events; Details 8.01.
- 2023-10-25: Form 8-K; Period of report 2023-10-24; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2023-10-23: Form 8-K; Period of report 2023-10-18; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-11-24 | 8-K/A | 2023-10-31 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously reported in the Original 8-K, on October 31, 2023, the Company received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company had evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. | d472003d8ka.htm |
| 2023-11-01 | 8-K | 2023-10-31 | 8.01 Other Events | 8.01 On November 1, 2023, the Company issued a press release announcing that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on October 31, 2023 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. | d544172d8k.htm |
| 2023-10-25 | 8-K | 2023-10-24 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On October 24, 2023, the Company issued a press release announcing the results of four new studies supporting the T2Bacteria® Panel, the T2Candida® Panel and the T2Resistance® Panel that were recently presented at the IDWeek conference in Boston, Massachusetts. 8.01 On October 24, 2023, the Company reported the following four new studies supporting the T2Bacteria® Panel, the T2Candida® Panel and the T2Resistance® Panel that were recently presented at the IDWeek conference in Boston, Massachusetts. | d573414d8k.htm |
| 2023-10-23 | 8-K | 2023-10-18 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d884334d8k.htm |
| 2023-10-17 | 8-K | 2023-10-12 | 2.02 Results of Operations and Financial Condition | 2.02 On October 12, 2023, the Company issued a press release announcing its financial results for its fiscal quarter ended September 30, 2023, and held a conference call to discuss those results. | d561275d8k.htm |
| 2023-10-12 | 8-K | 2023-10-12 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 On October 12, 2023, T2 Biosystems, Inc. (the “Company”) issued a press release announcing preliminary financial results for its third quarter ended September 30, 2023. 7.01 On October 12, 2023, the Company issued a press release announcing the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii. | d551631d8k.htm |
| 2023-10-12 | 8-K | 2023-10-12 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.03 To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. 5.03 As previously disclosed, on September 15, 2023, T2 Biosystems, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”), at which the Company’s stockholders voted to approve an amendment to the Company’s restated certificate of incorporation (the “Certificate of Incorporation”) to effect a reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a reverse split ratio ranging from any whole number between and including 1-for-50 and 1-for-150, with the exact ratio to be determined at the discretion of the Board of Directors of the Company (the “Board”). | d468619d8k.htm |
| 2023-09-18 | 8-K | 2023-09-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 T2 Biosystems, Inc. (the “Company’”) held its annual meeting of stockholders on September 15, 2023 (the “Annual Meeting”). 5.07 At the Annual Meeting, stockholders holding and entitled to vote 290,195,720 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) held as of the close of business on July 21, 2023 (the “Record Date”) and 1,000 shares of the Company’s Series A convertible preferred stock (the “Series A preferred stock”) held as of the Record Date, constituting 100% of the outstanding shares of Series A preferred stock and entitled to 400,000,000 votes (or 400,000 votes per share) solely with respect to the proposal to effect a Reverse Stock Split (as defined below) were present either by attendance via live webcast or by proxy. | d527537d8k.htm |
| 2023-08-11 | 8-K | 2023-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2023, the Company issued a press release announcing its financial results for its fiscal quarter ended June 30, 2023, and held a conference call to discuss those results. | d641513d8k.htm |
| 2023-08-09 | 8-K | 2023-08-08 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On August 9, 2023, T2 Biosystems, Inc. (the “Company”) issued a press release announcing the receipt of a letter from the Nasdaq Stock Market LLC (“Nasdaq”) on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) for continued listing on the Nasdaq Capital Market. 8.01 On August 8, 2023, the Company received written notice from the Nasdaq informing the Company that it has regained compliance with the MVLS Rule for continued listing on the NASDAQ Capital Market. | d510454d8k.htm |
| 2023-07-31 | 8-K | 2023-07-27 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On July 31, 2023, T2 Biosystems, Inc. (the “Company”) issued a press release announcing the receipt of a letter from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Nasdaq had granted the Company’s request for an exception to the minimum bid price requirements under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and the market value of listed securities requirements under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) until November 20, 2023. 8.01 As previously disclosed, the Company received written notice from the Nasdaq indicating that the Company had failed to maintain compliance with the minimum bid requirement under the Bid Price Rule and the MVLS Rule. | d521942d8k.htm |
| 2023-07-20 | 8-K | 2023-07-20 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On July 20, 2023, the Company issued a press release announcing that the FDA had informed the Company that its application for Breakthrough Device Designation for the Company’s Candida auris direct-from-blood molecular diagnostic test had been granted. 8.01 On July 20, 2023, the Company announced that the FDA had informed the Company that its application for Breakthrough Device Designation for the Company’s Candida auris direct-from-blood molecular diagnostic test had been granted. | d513985d8k.htm |
| 2023-07-12 | 8-K | 2023-07-12 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On July 12, 2023, the Company issued a press release announcing its financial results for its fiscal quarter ended June 30, 2023. 8.01 • Achieved second quarter total revenue of $2.0 million, comprised entirely of product revenue. | d534607d8k.htm |
| 2023-07-06 | 8-K | 2023-07-03 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 On July 5, 2023, T2 Biosystems, Inc. (the “Company”) entered into a Purchase Agreement (the “Series A Purchase Agreement”) with CRG Partners III L.P., CRG Partners III - Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund “B” (Cayman) L.P. (collectively in such capacity, the “Purchasers”), pursuant to which the Company agreed to issue and sell a total of 1,000 shares of the Company’s newly designated Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred”), to the Purchasers for a purchase price of $100.00. 3.02 The disclosure included in Item 1.01 of this report is incorporated under this Item by reference. 5.03 On July 5, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of the State of Delaware pursuant to the Series A Purchase Agreement. | d486699d8k.htm |
| 2023-06-23 | 8-K | 2023-06-20 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 20, 2023, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last ten consecutive business days, the bid price for the Company’s common stock had closed below the minimum $0.10 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stock Rule”). | d504829d8k.htm |
| 2023-06-09 | 8-K | 2023-06-09 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On June 9, 2023, T2 Biosystems, Inc. (the “Company”) issued a press release announcing a collaborative relationship with Vanderbilt University Medical Center’s Learning Healthcare System Platform. 8.01 On June 9, 2023, the Company announced a collaborative relationship with Vanderbilt University Medical Center’s Learning Healthcare System Platform. | d444448d8k.htm |
| 2023-06-05 | 8-K | 2023-06-05 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On June 5, 2023, T2 Biosystems, Inc. (the “Company”) issued a press release announcing that it has submitted an application with the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for the Company’s Candida auris test. 8.01 On June 5, 2023, the Company issued a press release announcing that it has submitted an application with the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for the Company’s Candida auris test. | d511068d8k.htm |
| 2023-05-30 | 8-K | 2023-05-30 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On May 30, 2023, T2 Biosystems, Inc. (the “Company”) issued a press release announcing that its distribution partner, Biomedica Poland, secured a multi-year contract for T2Dx Instruments and sepsis test panels in Poland. 8.01 On May 30, 2023, the Company issued a press release announcing that its distribution partner, Biomedica Poland, secured a multi-year contract for T2Dx Instruments and sepsis test panels in Poland. | d423227d8k.htm |
| 2023-05-25 | 8-K | 2023-05-23 | 2.02 Results of Operations and Financial Condition | 2.02 On May 23, 2023, the Company issued a press release announcing its financial results for its fiscal quarter ended March 31, 2023, and held a conference call to discuss those results. | d473593d8k.htm |
| 2023-05-23 | 8-K | 2023-05-23 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On November 22, 2022, we received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (“MVLS”) had been below the $35 million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). | d447004d8k.htm |
| 2023-03-31 | 8-K | 2023-03-31 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On March 30, 2023, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). | d468341d8k.htm |
| 2023-03-16 | 8-K | 2023-03-13 | 2.02 Results of Operations and Financial Condition | 2.02 On March 13, 2023, the Company issued a press release announcing its financial results for its fiscal quarter and fiscal year ended December 31, 2022, and held a conference call to discuss those results. | d487064d8k.htm |
| 2023-02-16 | 8-K | 2023-02-14 | 8.01 Other Events | 8.01 On February 14, 2023, T2 Biosystems, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Craig-Hallum Capital Group LLC, as representatives of the several underwriters named in Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten offering of 9,018,519 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), in lieu of Common Stock for certain investors, pre-funded warrants (“Pre-funded Warrants”) to purchase 2,092,592 shares of Common Stock, and warrants (“Warrants”) to purchase 22,222,222 shares of Common Stock (collectively, the “Offering”). | d426940d8k.htm |
| 2023-02-13 | 8-K | 2023-02-13 | 8.01 Other Events | 8.01 On February 13, 2023, T2 Biosystems, Inc. issued a press release announcing the completion of its clinical trial for the T2Biothreat Panel, with results that demonstrated very high sensitivity and specificity across all six targets. | d456659d8k.htm |
| 2023-01-23 | 8-K | 2023-01-17 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 As previously reported, on September 8, 2021, the Company entered into a 10-year lease agreement (the “Lease”) with Farley White Concord Road, LLC (the “Landlord”), pursuant to which the Company leased approximately 70,125 square feet for its occupancy and use as office, laboratory and commercial manufacturing space at 290 Concord Road, Billerica, Massachusetts (the “Premises”). 2.02 On January 23, 2023, the Company issued a press release announcing its financial results for its fiscal quarter and full year ended December 31, 2022. | d452632d8k.htm |